Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients

Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients: Double-Blinded, Randomised Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02874378

Enrollment

100

Registered

2016-08-22

Start date

2016-10-31

Completion date

2017-12-31

Last updated

2017-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure

Brief summary

Postoperative renal function recovery is very important to value the operation quality after kidney transplantation. Dexmedetomidine is a selective alpha-2 agonist,enhances urine flow rate and perioperative renal function. Some animal experiments have revealed its beneficial effects against ischemia-reperfusion injury (IRI), our goal is therefore to investigate the effectiveness of a recipient treatment with Dexmedetomidine during operation at reducing Cystatin C level and enhancing renal function after kidney transplantation.

Detailed description

Participants will be randomly assigned, in a 1:1 ratio, to receive Dexmedetomidine or control (0.9 %Sodium Chloride Solution,0.9%NaCl). The randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center.Dexmedetomidine and 0.9 %NaCl solution will be treated from 10 minutes before anesthesia induction, ending in the last 10 minutes before the operation to complete. Cystatin C level and urine volume (but are not limited to these data) at 1,7,14 days after the transplantation will be recorded. The participation of each patient is scheduled for 14 days.Investigators will research both living and cadaveric kidney transplants.

Interventions

DRUGDexmedetomidine

DRUG0.9%NaCl solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

17 Years to 65 Years

Healthy volunteers

Inclusion criteria

Patients underwent renal transplant in the First Affiliated Hospital of Xi'an Jiaotong University.

Exclusion criteria

severe comorbidity history: severe cardiac dysfunction, central nervous system disease, endocrine, and history of mental disorders; alcoholic and long-term use of sedatives and opioids history; drug allergy history.

Design outcomes

Primary

Measure	Time frame
Cystatin C level	2 weeks

Secondary

Measure	Time frame
average daily urinary volume	2 weeks
length of hospital stay (LOS)	an expected average of 2 weeks
Wake up time, extubation time,SAS score,PONV	up to 6 hours
total dosage of remifentanil	up to 4 hours
Cr/GFR improvement	2 weeks

Countries

China

Contacts

Primary ContactJing Xu, MD

xuj0909@163.com13772052823

Backup ContactQiang Wang, PHD

dr.wangqiang@139.com13991236768

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026